Johnson & Johnson said Tuesday that it is on track to meet its target of 100 million coronavirus vaccine doses for the United States by the end of June, one of a string of confident announcements on vaccine supply.
Johnson & Johnson is being closely watched as a potential third vaccine for the U.S., helping further an increase in available doses. The company said Tuesday that it expects results from its Phase 3 trial “by early next week.”
If the vaccine proves to be safe and effective and is authorized in the coming weeks, the company’s chief financial officer, Joseph Wolk, told CNBC: “We’re very confident and on track to meet all of our commitments, which would include 100 million doses to the U.S. by the end of June.”
Read more at The Hill.